RAS testing for colorectal cancer

Click to increase image sizeClick to decrease image size

Disclaimer

The opinions expressed in this article are those of the interviewee and do not necessarily reflect the views of Future Medicine Ltd.

Financial & competing interests disclosure

HJ Lenz has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Additional information

Notes on contributors

Heinz-Josef Lenz

Dr Heinz-Josef Lenz is a professor of medicine in the USC Departments of Medicine and Preventive Medicine, Kathryn M Balakrishnan Chair for Cancer Research, Scientific Director of the Cancer Genetics Unit, Director of the Gastrointestinal Oncology Program and Co-Director of the Colorectal Center at the USC Norris Comprehensive Cancer Center (CA, USA). Dr Lenz earned his MD at the Johannes-Gutenberg Universität in Mainz, Germany. In 1991, he completed his internship, residency and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany. He obtained a special fellowship training at Universität Wien (Austria), George Washington University (DC, USA) and Harvard Medical School (MA, USA). In 1991, he received the prestigious Research Fellowship Award from the Deutsche Krebshilfe (Bonn, Germany). He completed his research fellowship in biochemistry and molecular biology at the USC Norris Comprehensive Cancer Center before joining USC in 1994. He was awarded a Career Development Award from STOP CANCER (1994–1997). Based on his research, he also received a Young Investigator Award from the American Society of Clinical Oncology (ASCO) in 1994. In 1995, Dr Lenz was selected for the prestigious ASCO Career Development Award. The National Cancer Institute-funded laboratory of Dr Lenz has been interested in the identification and determination of molecular markers in precancerous and cancerous tissues that might predict cancer risk and clinical outcome in gastrointestinal and breast cancer. Dr Lenz is also the Institutional Principal Investigator on the UO1/NIH contract (California Cancer Consortium, USA) in collaboration with City of Hope and UC Davis (CA, USA), which allows him to design innovative clinical trials with novel promising anticancer drugs.